A Study of JNJ-64300535 in Healthy Participants

A Phase 1 Open-label Study to Assess the Immunogenicity, Safety, and Reactogenicity of JNJ-64300535, a DNA Vaccine Administered by Electroporation-mediated Intramuscular Injection, in Healthy Participants

The purpose of this study is to evaluate the cellular immunogenicity of 3 monthly electroporation-mediated intramuscular (IM) injections of JNJ-64300535 in healthy participants.

Inclusion Criteria:

• Must sign an informed consent form (ICF) indicating that he understands the purpose, procedures and potential risks and benefits of the study, and is willing to participate in the study
• Willing and able to adhere to the prohibitions and restrictions specified in this protocol
• Must be healthy as confirmed by medical history, physical examination, and vital signs performed at screening

Exclusion Criteria:

• Weight of less than (<) 50 kilograms (kg) and a body mass index (BMI) <19.0 or greater than (>) 29.9 kilogram per meter square (kg/m^2) at screening
• History of Human Immunodeficiency Virus (HIV) infection or a positive HIV antibody test at screening
• History of HBV infection, measured by the presence of HBsAg and/or anti-HBc antibodies
• History of seizure disorders unless seizure free for >5 years
• Has a non-removable active electronic stimulation device